Pacific Edge gets FMA warning over disclosure, must compensate shareholders

Pacific Edge gets FMA warning over disclosure, must compensate shareholders
By Jonathan Underhill May 25 (BusinessDesk) - Pacific Edge, which commercialised a non-invasive test for bladder cancer, has agreed to make a $500,000 compensation payment to shareholders after an investigation by the Financial Markets Authority found that the company probably breached NZX listing rules on continuous disclosure. The regulator issued a public warning to Pacific Edge after investigating delays in disclosing new contracts in 2013. The compensation payment will go to shareholders who sold the stock in the window between the c...